Table of Contents
- Trial overview
- Who is being studied
- Trial phases and study design
- Outcomes being measured
- What the study may show
Trial overview
This clinical trial is an interventional study, which means the research team gives the study treatment and then measures the results.[1] The study is authorised and is evaluating Gr0015 in adults with alpha-1 antitrypsin deficiency-associated lung disease and/or liver disease.[1]
The trial title describes it as a dose-exploration and dose-expansion study, so the researchers are first learning about the best dose and then studying that dose in more people.[1]
Who is being studied
The target population is adult patients with alpha-1 antitrypsin deficiency-related lung disease and/or liver disease.[1] This means the study is not for children and is focused on people whose lungs, liver, or both are affected by this inherited condition.[1]
The condition studied is listed as Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease.[1] In simple terms, alpha-1 antitrypsin deficiency is a genetic disorder, meaning it is passed through families.[1]
Trial phases and study design
This is a Phase 1/2 trial.[1] Phase 1 usually focuses on safety and tolerability, while Phase 2 looks more closely at whether the treatment may help the disease.[1]
The study includes two main parts: Phase 1 (Dose Exploration) and Phase 2 (Dose Expansion).[1] Dose exploration means the researchers are testing and learning which dose is most suitable, and dose expansion means they give that dose to more participants to gather more information.[1]
The planned enrollment is 184 participants.[1] Enrollment is the number of people the study plans to include.[1]
Outcomes being measured
The main goal in Phase 1 is to evaluate safety and tolerability of Gr0015 and to help find the optimal biological dose (the dose that gives the best biological effect for the study).[1]
The primary endpoint in Phase 1 is the rate of treatment-emergent adverse events and serious adverse events.[1] Adverse events are unwanted medical problems seen during the study, and serious adverse events are the more severe ones.[1]
The main goal in Phase 2 is to evaluate efficacy, meaning whether the treatment shows a helpful effect, based on pharmacodynamic activity.[1] Pharmacodynamic activity means changes in the body that suggest the treatment is doing what it is supposed to do in the study.[1]
The Phase 2 primary endpoint is the absolute blood levels of total AAT, Z-AAT, and M-AAT.[1] These are blood measurements the researchers use to track the biological effect of the study treatment.[1]
What the study may show
This trial is designed to answer two main questions: first, whether Gr0015 is safe and tolerable in adults with AATD-related lung and/or liver disease, and second, whether it shows early signs of benefit in the body.[1] The study does not yet provide a final answer about long-term benefit, but it is an important step in early clinical research.[1]
Because the trial includes both dose finding and dose expansion, it may help researchers choose the best dose for later studies if the results are promising.[1]
